SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies
Review on CD19 in Diffuse large B-cell lymphoma, in Clinical Cancer Research (2011), one of the most cited Europe PMC records with CD19 in its title.
Overview
SAR3419 is a novel anti-CD19 humanized monoclonal antibody conjugated to a maytansine derivate through a cleavable linker for the treatment of B-cell malignancies. SAR3419 combines the strengths of a high-potency tubulin inhibitor and the exquisite B-cell selectivity of an anti-CD19 antibody. The internalization and processing of SAR3419, following its binding at the surface of CD19-positive human lymphoma cell lines and xenograft models, release active metabolites that trigger cell-cycle arrest and apoptosis, leading to cell death and tumor regression. SAR3419 has also been shown to be active in different lymphoma xenograft models, including aggressive diffuse large B-cell lymphoma, resulting in complete regressions and tumor-free survival. In these models, the activity of SAR3419 compared favorably with rituximab and lymphoma standard of care chemotherapy. Two phase I trials with 2 different schedules of SAR3419 as a single agent were conducted in refractory/relapsed B-cell non-Hodgkin lymphoma. Activity was reported in both schedules, in heavily pretreated patients of both follicular and diffuse large B-cell lymphoma subtypes, with a notable lack of significant hematological toxicity, validating SAR3419 as an effective antibody-drug conjugate and opening opportunities in the future. Numerous B-cell-specific anti-CD19 biologics are available to treat B-cell non-Hodgkin lymphoma, and early phase I results obtained with SAR3419 suggest that it is a promising candidate for further development in this disease. In addition, thanks to the broad expression of CD19, SAR3419 may provide treatment options for B-cell leukemias that are often CD20-negative.
Indexed on Europe PMC as PubMed record 22003072 (DOI 10.1158/1078-0432.ccr-11-0485). Its title names CD19 and its text names Diffuse large B-cell lymphoma; PubMed types it as a review (Review). It was matched automatically to the idea "In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma" and no figure has been checked by an editor.
One of the most cited reviews Europe PMC returns for CD19 in Diffuse large B-cell lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
- Matched by CD19 in the title and Diffuse large B-cell lymphoma in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.
- A review summarises other studies; the primary reports it cites are the evidence.
Similar pages
not linked directly; found by shared links- Key paperEfficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma.
- Key paperThe long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma.
- TrialStudy of Out of Specification for Tisagenlecleucel
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma.
- TrialRELIANCE
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma.
- TrialZUMA-1
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma.
- TrialTalicabtagene autoleucel (NexCAR19) phase 1/2
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma.
- TrialZUMA-7
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma.